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Abstract: We investigated the effect of ATP-MgCl2 on myocardial hemodynamics and metabolism.
The study included 12 mongrel dogs that were randomly divided into 2 groups: the control and the ATP-MgCl2 (study) groups.
Following a right thoracotomy, the left anterior descending artery was ligated for 15 min and then reperfusion was performed.
After the ischemic period, cardiopulmonary bypass was initiated and the aorta was cross-clamped. ATP-MgCl2 (70+70 mmol/l) 0.25
ml/kg per h was given to the study group at the start of the ischemic period. Hemodynamic and metabolic measurements were
obtained at basal, and then after 60, 120, and 180 min of reperfusion
Cardiac output values were significantly higher in the study group; at the end of the third hour of reperfusion they were 2370 ±
31 ml/min in the study group and 900 ± 45 ml/min in the control group (P < 0.05). Myocardial Oxygen Extraction (MOE) and
Myocardial Lactate Extraction (MLE) values were significantly higher in the control group; at the end of the third hour of the
reperfusion MOE values were 50 ± 2 ml in the study group and 55 ± 3 ml in the control group, while MLE values were -0.06 ±
0.02 mmol/ml in the study group and -0.12 ± 0.07 mmol/ml in the control group (P < 0.05).
Hemodynamic and metabolic parameters revealed that the use of ATP-MgCl2 might be beneficial in reducing ischemia-reperfusion
damage.
Key Words: In vivo experimental study, ischemia-reperfusion injury, myocardium, ATP-MgCl2

ATP-MgCl2 Kullan›m›n›n Myokard Hasar›na Etkisi; ‹n Vivo Deneysel Çal›flma
Özet: Bu çal›flmada iskemi-reperfüzyon hasar›nda ATP-MgCl2 kullan›m›n›n myokard üzerine etikisi hemodinamik ve metabolik
parametreler yard›m› ile araflt›r›ld›.
Oniki adet sokak köpe¤i, ATP-MgCl2 ve kontrol olmak üzere 2 eflit gruba rastgele olarak ayr›larak çal›flmada kullan›ld›. Bu ifllemi
izleyerek hayvanlara sa¤ torakotomi yap›ld› ve perikard aç›ld›. Sol anterior desendens arteri 15 dakika süre ile ligatüre edilerek
iskemik b›rak›ld› ve daha sonra ligatür aç›larak reperfüzyon yap›ld›. Daha sonra kardiyopulmoner bypasa girildi. Aortaya kros-klemp
konulmas›n› takiben, aorta asendense konulan bir kanül yard›m› ile so¤uk kristaloid kardioplejik verilerek kardiak arrest sa¤land›.
Çal›flma grubuna perfüzyon bafllang›c›ndan itibaren ATP-MgCl2 (70+70 mmol/l) 0,25 ml/kg/saat h›z›nda verildi, kontrol grubunda
hiçbir sa¤alt›m yap›lmad›. Hemodinamik ve metabolik ölçümler bazal, 60 dakika, 120. dakika ve 180. dakikalarda al›nd›.
Çal›flmam›zda; kardiak output de¤erleri çal›flma grubunda anlaml› olarak yüksekti. Çal›flma ve kontrol grubunda 3. saatte 2370 ±
31 ml/dk ve 900 ± 45 ml/dk (P < 0,05) idi. MOE (miyokardial oksijen ekstraksiyonu) ve MLE (miyokardial laktat ekstraksiyonu)
kontrol grubunda anlaml› olarak yüksekti. MOE perfüzyonun 3. saati sonunda çal›flma grubunda 50 ± 2 ml, kontrol grubunda 55 ±
3 ml ve MLE ise çal›flma grubunda - 0,06 ± 0,02 mmol/ml, kontrol grubunda - 0,12 ± 0,07 mmol/ml idi (P < 0,05).
Bu çal›flma sonucunda; ATP-MgCl2 kullan›m› iskemi-reperfüzyon yaralanmalar›nda hemodinamik ve metabolik parametreleri
düzeltmesi aç›s›ndan faydal› bulunmufltur.
Anahtar Sözcükler: ‹n vivo deneysel çal›flma, iskemi-reperfüzyon hasar›, myokard, ATP-MgCl2
*E-mail: zsaritas@aku.edu.tr
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Introduction
Open-heart surgery has been successfully performed
for a long time as a result of technological developments
in the application of cardiopulmonary bypass (CPB). In
spite of the improvements in cardiovascular surgery,
cardiopulmonary bypass systems have not yet reached an
ideal level. Despite the great developments in the
application of CPB during the last 30 years and presently
available technical and pharmacological possibilities,
patients that have undergone coronary artery bypass
grafting (CABG) surgery have experienced insufficient
myocardial protection (1,2).
As stated above, myocardial damage occurs mostly
during the ischemia-reperfusion period. Therefore,
studies dealing with new drugs have been conducted, and
technical methods for shortening myocardial ischemia
duration, for increasing the tolerance of ischemia, and
consequently reducing reperfusion damage have been
investigated (3-5). Murry et al. (6) showed that brief
periods of myocardial ischemia protect the myocardium
from ischemia-reperfusion damage and endogenous
adenosine rising up in the preconditioning period is a
protective factor during the ischemia-reperfusion period.
Myocardial ischemia is a pathology characterized by
decreased myocardial energy storage and ventricular
function. Unless sufficient blood flow is re-established,
myocardial tissue necrosis occurs. The important
determinants of cell death are the duration and extent of
myocardial ischemia, as well as the absence of supportive
collateral flow and the acceleration of myocardial tissue
damage (7).
In the literature, it has been determined that the
amounts of interruption of myocardial blood flow and
ischemia duration are correlated with myocardial damage
(8,9).
Adenosine triphosphate (ATP) sources rapidly
decrease in the 3-4 min following ischemia. At the same
time, the oxidative phosphorylation process, the fuel
source of cell metabolism, completely stops. As a result,
intracellular ion hemostasis breaks down. Impaired
calcium transportation results in cell damage. Liquid
peroxidation, which occurs during the reperfusion period
following ischemia, as a result of radical free oxygen
formation, causes cell membrane damage and
microvascular spasm (10-12).
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Adenosine triphosphate-magnesium chloride (ATPMgCl2), which has been investigated for a long time, is a
valuable drug for treating the hazardous effects of organ
ischemia-reperfusion. Its use in organ ischemia and shock
continues to be investigated (13,14). The amount of
magnesium decreases in ischemic injuries, which results in
damage to cell membrane integrity, ATPase function,
and, especially, production of co-factors involved in
energy formation. Magnesium is an important cation that
plays key roles in cell metabolism, including membrane
synthesis, membrane integrity, protein synthesis, calcium
transportation, and aerobic respiration. High doses of
magnesium should be used to obtain these benefits (1517).
The use of ATP-MgCl2 results in increased uptake of
magnesium into the cell. In addition, the use of ATPMgCl2 during the reperfusion period corrects microcirculatory dysfunction, decreases cell edema, improves
organ blood flow, refreshes the intracellular ATP level,
and regulates endothelial function after ischemia or shock
(18-21).
In this study, we investigated the use of ATP-MgCl2
for the prevention of ischemia-reperfusion injury, and to
determine whether it has any effects on myocardium
hemodynamic and metabolic parameters.

Materials and Methods
The study included 12 mongrel dogs (24 ± 3 kg); 6
were in the study group (ATP-MgCl2) and 6 were in the
control group. The study was conducted in the surgery
department of Ankara University, Veterinary Faculty,
Ankara, Turkey. Before starting our investigation, all of
the dogs were quarantined for 15 days, and routine
clinical examinations and antiparasite therapy were
administered. Ethical Committee approval was given for
this study and the animal care and use complied with the
“Principles of Laboratory Animal Care” and the “Guide for
the Care and Use of Laboratory Animals”.
The animals received no food during for 12 h before
the operation, and were premedicated with subcutaneous
atropine sulfate (0.04 mg/kg) 30 min before the
operation and with intramuscular xylazine hydrochloride
(2 mg/kg) 15 min before the operation. Anesthesia was
induced with intravenous fentanyl citrate and sodium
pentothal. After respiratory depression was maintained,
all animals were intubated for ventilatory support. A
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thermodilution catheter was introduced into the
pulmonary artery via the external jugular vein. Heart rate
and rhythm were recorded.
After administration of adequate anesthesia, a right
thoracotomy was made and the pericardium was opened.
The left anterior descending artery was ligated to obtain
ischemia for 15 min and than the ligature was removed
to obtain reperfusion. After that, cardiopulmonary bypass
was initiated using 2 venous cannulas placed in the caudal
and cranial vena cava, and an arterial cannula placed in
the femoral artery. Bypass flow was adjusted to
approximately 100 ml/kg and the alpha-stat strategy was
used to hold PCO2 between 35 and 45 mmHg. Priming
volume for the membrane oxygenator was prepared with
ringer lactate (1000 ml), mannitol (1 mg/kg), heparin
(5000 IU), and sodium bicarbonate (30 mEq). A 40 µm
arterial filter was placed in the arterial line. After crossclamping the aorta, antegrade cold crystalloid
cardioplegia (St. Thomas no.2) was perfused from the
ascending aorta via a cannula in order to maintain cardiac
arrest. ATP-MgCl2 (70+70 mmol/l) was given to the
study group with an infusion rate of 0.25 ml/kg per h; no
medication was administered to the control group.
Hemodynamic and metabolic measurements were taken
at basal, and then after 60, 120, and 180 min of
reperfusion.

Hemodynamic measurements
Cardiac output was measured with the help of a
thermodilution catheter. Heart rate and pressure were
monitored and recorded.

Metabolic measurements
The HYDRAGEL ISO-CK kit (Sebia, Hydragel ISO-CK
kit) was used for the separation and calculation of
isoenzymes of creatine phosphokinase in serum by
agarose gel electrophoresis. Following the determination
of fractions, total activity of creatine phosphokinase was
determined with a Hitachi 911 analyzer and BoehringerMannheim kits. Activities of the fractions (isoenzymes)
are reported as percentage of total activity.
Myocardial oxygen extraction (MOE) was calculated
using the equation: MOE = Ca – Cv/Ca, where Ca and Cv
are the arterial oxygen content and coronary sinus oxygen
content, respectively. The oxygen content of the aorta

and coronary sinus was measured automatically with an
OSM-3 Hemoximeter radiometer (Denmark).
The blood samples were immediately put into
perchloric acid for lactate measurements and they were
prepared for measurement by the enzymatic
spectrophotometric method the same day. Myocardial
lactate extraction (MLE) was calculated using the
equation: MLE = AoL – CsL/AoL, where AoL and CsL show
the aortic lactate level and the coronary sinus lactate level,
respectively.

Statistical analysis
All data were compared with mean ± standard
deviation. The level of significance was set at P < 0.05.
Comparison between the groups was made with
Student’s t-test.

Results
There were no significant differences between the
study and control groups with regard to mean arterial
pressure, but cardiac output values were significantly
higher in the study group after 60, 120, and 180 min of
reperfusion. Cardiac output values in the study and
control groups at 180 min were 2370 ± 31 ml/min and
900 ± 45 ml/min, respectively (P < 0.05). Measurements
of mean pulmonary artery pressure and pulmonary
capillary wedge pressure (PCWP) were significantly
higher in the control group. PCWP values in the study and
control groups after 180 min were 9.5 ± 0.7 mmHg and
15.4 ± 3.5 mmHg, respectively (P < 0.05) (Table 1).
MOE and MLE values were significantly higher in the
control group. MOE was 50 ± 2 ml in the study group
and 55 ± 3 ml in the control group after 180 min of
reperfusion (P < 0.05). MLE was measured as –0.06 ±
0.02 mmol/ml in the study group and –0.12 ± 0.07
mmol/ml in the control group after 180 min of
reperfusion (P < 0.05). CPK-MB values were significantly
higher in the control group compared with the study
group after 180 min of reperfusion (26 ± 3 IU/l vs. 44 ±
5 IU/l; P < 0.05) (Table 2).

Discussion
Myocardial damage occurs during the ischemiareperfusion (IR) period. Studies about new drugs and
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Table 1.

Hemodynamic values of the study and control groups (* P < 0.05). MAP: mean arterial pressure; MPAP: mean pulmonary arterial pressure;
PCWP: pulmonary capillary wedge pressure; CO: cardiac output.

ATP-MgCl2 Group:
0 min
HR (/min)
MAP (mmHg)
MPAP (mmHg)
PCWP (mmHg)
CO (ml/min)

104.8 ± 26.8
84.6 ± 14.3
14.0 ± 5.6
16.5 ± 2.1 *
1285 ± 54

60 min

120 min

93.3 ± 15.6
35.8 ± 22.6
13.5 ± 3.5*
10.5 ± 0.7*
1893 ± 64*

75.3 ± 12.8 *
36.3 ± 20.2
14.5 ± 0.7 *
11.5 ± 0.7 *
1933 ± 63 *

180 min
62.8 ± 11.8 *
32.8 ± 22.4
11.5 ± 0.7 *
9.5 ± 0.7 *
2370 ± 31 *

Control Group:
0 min
HR (/min)
MAP (mmHg)
MPAP (mmHg)
PCWP (mmHg)
CO (ml/min)

112.4 ± 13.5
92.3 ± 11.5
14.5 ± 5.2
9.5 ± 3.2 *
1300 ± 50

60 min

120 min

180 min

116.1 ± 11.6
56.7 ± 10.2
22.5 ± 6.5 *
16.3 ± 3.5 *
900 ± 40 *

115.2 ± 8.5 *
50.2 ± 9.4
23.2 ± 5.4 *
15.1 ± 2.6 *
925 ± 45 *

113.1 ± 6.8 *
45.0 ± 13.6
18.3 ± 6.1 *
15.4 ± 3.5 *
900 ± 40 *

Table 2. Metabolic values of the study and control groups (* P < 0.05). MOE: myocardial oxygen extraction; MLE: myocardial lactate extraction;
CPK-MB: creatine phosphokinase-myocardial band.
0.min

60.min

120.min

180.min

52 ± 3
50 ± 2

*
61 ± 3
54 ± 3

*
57 ± 2
51 ± 2

55 ± 3
50 ± 2

MLE (mmol/ml)
Control
ATP-MgCl2

–0.01 ± 0.002
–0.02 ± 0.001

*
–0.16 ± 0.03
–0.09 ± 0.02

*
–0.13 ± 0.05
–0.05 ± 0.03

*
–0.12 ± 0.07
–0.06 ± 0.02

CPK-MB (IU/l)
Control
ATP-MgCl2

26 ± 4
24 ± 3

37 ± 9
28 ± 6

*
48 ± 10
31 ± 4

*
44 ± 5
26 ± 3

MOE (ml)
Control
ATP-MgCl2

techniques that reduce this damage are ongoing (3-5).
Murry et al. (6) declared that endogenous adenosine was
a protective factor during the IR period. In the present
study, the effect of ATP-MgCl2 on myocardial damage
during the IR period was investigated.
ATP-MgCl2, which has been investigated for a long
time, is reported to be a useful drug in overcoming the
hazardous effects of organ IR. Its use during organ
ischemia and shock continues to be investigated (13,14).
Evaluating the results of our study, we can claim that use
of ATP-MgCl2 improves hemodynamic and metabolic
parameters during the IR injury period. No statistical
difference was seen between the control and study
groups in terms of mean arterial blood pressure. The
measurements of cardiac output in the study group were
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much higher compared to the control group values. As a
result, it can be said that the use of ATP-MgCl2 had a
beneficial effect on hemodynamic parameters.
Additionally, it was observed that pulmonary artery and
pulmonary capillary wedge pressure results were very
high in the control group.
The amount of magnesium decreases in ischemic
injuries. Lack of magnesium results in damage to cell
membrane integrity, ATPase function, and, especially,
production of co-factors involved in energy formation.
Magnesium is an important cation that plays key roles in
cell metabolism, including membrane synthesis,
membrane integrity, protein synthesis, calcium
transportation, and aerobic respiration. High doses of
magnesium should be used to obtain these benefits (15-
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17). Since high-doses of magnesium may have adverse
effects, ATP-MgCl2 was used in our study. The use of
ATP-MgCl2 increases the cellular uptake of magnesium.
The use of ATP-MgCl2 during the reperfusion period
corrects micro-circulatory dysfunction, decreases cell
edema, improves organ blood flow, refreshes intracellular
ATP level, and regulates endothelial function after
ischemia or shock (18-21). It was noted that MOE and
MLE values were high in the control group; therefore, it
can be concluded that ATP-MgCl2 improved intracellular
functional damage in the study group.
Satisfactory results have been obtained in terms of
hemodynamic and metabolic parameters using ATPMgCl2. ATP-MgCl2, which has been previously found to be

useful in different organ ischemia and shock models, was
also found to be effective in our study (13,14,20).
In conclusion, the in vivo use of ATP-MgCl2 was useful
in improving hemodynamic and metabolic parameters
during IR injury. Additional studies concerning ATP-MgCl2
are needed to demonstrate its beneficial effects during IR
injury.
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